This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Exocrine pancreatic insufficiency (EPI) in type 3c diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pancreatic exocrine insufficiency in diabetes

  • pancreatic exocrine insufficiency (EPI) is characterised by a deficiency of three major groups of pancreatic enzymes (amylase, protease, lipase):
    • causes an impairment in digestion and consequent nutrient malabsorption and malnutrition
  • patients with type 1 or type 2 DM have been shown to have reductions in fecal elastase levels, with some pathologic changes similar to chronic pancreatitis (CP), and this has been termed "diabetic exocrine pancreatopathy"


  • prevalence of EPI has been stated as an average of 40% in type 1 DM and 27% in type 2 DM (3)

  • co-existing EPI in people with either type 1 or type 2 diabetes is likely to be a different clinical entity to pancreatic diabetes (sometimes referred to as type 3c diabetes) (4)
    • type 3c diabetes is diabetes due to pancreatic disease or injury so both endocrine and exocrine hormone production are affected
    • most commonly identified cause of type 3c diabetes is chronic pancreatitis

Clinical features of EPI:

  • patients have varying degrees of exocrine and endocrine dysfunction
    • damage to the islet of Langerhans effects the secretion of hormones from the alpha, beta, and pancreatic polypeptide cells; the combination of low insulin, glucagon, and pancreatic polypeptide contributes to rapid fluctuations in glucose levels
      • form of "brittle diabetes" may result in the poorer glycemic control observed in patients with DEP/type 3c diabetes
      • patients are more likely to require early insulin initiation compared with those with T2DM
        • individuals should be advised about the symptoms of decompensated hyperglycemia, although they are less likely to develop ketoacidosis (5,6)
  • symptoms of EPI develop when approximately 90% of the exocrine function of the pancreas is lost
    • possible clinical features of EPI include steatorrhea (often without diarrhea), abdominal bloating, weight loss, various vitamin deficiencies, and metabolic bone disease (6)

glycaemic control following pancreatic enzyme replacement therapy (PERT)

  • pancreatic enzyme replacement therapy (PERT) can affect glycaemic control pathways via (7)
    • altered action of the hormones leptin and incretins on glucose homeostasis
      • PERT may lead to an improvement of incretin response to food and with consequent lower blood glucose levels
    • leading to improved absorption of oral diabetes medication
  • there is a need to frequently check a patient's glycaemic response and blood glucose levels during PERT as the dose of the diabetes medication may need adjustment (especially sulphonylureas and insulin)

Management

  • seek expert advice
  • is generally managed by starting with metformin, but insulin may eventually be needed
  • incretin therapy is avoided considering the risk of pancreatitis (8)
  • need consistent treatment of PEI (pancreatic exocrine insufficiency) to ensure nutrient absorption for prevention of hypoglycemia and additional vigilance to prevent hypoglycemia because of potential loss of counter-regulatory glucagon secretion (8)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.